Inozyme Pharma Inc
INZY4.000USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
257.88MMarket Cap
LossP/E TTM
More Details of Inozyme Pharma Inc Company
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Inozyme Pharma Inc Info
Ticker SymbolINZY
Company nameInozyme Pharma Inc
IPO dateJul 24, 2020
CEODr. Douglas A. (Doug) Treco, Ph.D.
Number of employees67
Security typeOrdinary Share
Fiscal year-endJul 24
Address321 Summer Street
CityBOSTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02210
Phone18573304340
Websitehttps://www.inozyme.com/
Ticker SymbolINZY
IPO dateJul 24, 2020
CEODr. Douglas A. (Doug) Treco, Ph.D.
Company Executives of Inozyme Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Mueller
Mr. Brian Mueller
Director
Director
--
--
Mr. Stefan Riley
Mr. Stefan Riley
Investor Relations
Investor Relations
--
--
Mr. G. Eric Davis
Mr. G. Eric Davis
President, Director
President, Director
--
--
Mr. Eric Fleekop
Mr. Eric Fleekop
Company Secretary, Director
Company Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Brian Mueller
Mr. Brian Mueller
Director
Director
--
--
Mr. Stefan Riley
Mr. Stefan Riley
Investor Relations
Investor Relations
--
--
Mr. G. Eric Davis
Mr. G. Eric Davis
President, Director
President, Director
--
--
Mr. Eric Fleekop
Mr. Eric Fleekop
Company Secretary, Director
Company Secretary, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Beryl Capital Management, LLC
9.79%
Longitude Capital Management Co., LLC
9.05%
Adage Capital Management, L.P.
7.99%
Pivotal Bioventure Partners Investment Advisor LLC
6.96%
Sofinnova Investments, Inc
6.63%
Other
59.58%
Shareholders
Shareholders
Proportion
Beryl Capital Management, LLC
9.79%
Longitude Capital Management Co., LLC
9.05%
Adage Capital Management, L.P.
7.99%
Pivotal Bioventure Partners Investment Advisor LLC
6.96%
Sofinnova Investments, Inc
6.63%
Other
59.58%
Shareholder Types
Shareholders
Proportion
Venture Capital
9.05%
Investment Advisor
0.10%
Other
90.85%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
217
63.12M
97.77%
-4.84M
2025Q1
223
54.92M
85.52%
-13.69M
2024Q4
214
60.27M
93.82%
-9.91M
2024Q3
191
62.40M
99.19%
-7.69M
2024Q2
189
61.61M
98.84%
-3.38M
2024Q1
182
57.68M
93.47%
-8.16M
2023Q4
168
57.62M
93.40%
-5.18M
2023Q3
173
55.08M
89.40%
+6.47M
2023Q2
167
38.83M
84.32%
-10.19M
2023Q1
159
36.61M
84.56%
-4.82M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Beryl Capital Management, LLC
--
0%
--
--
Longitude Capital Management Co., LLC
--
0%
--
--
Sofinnova Investments, Inc
--
0%
--
--
Glazer Capital, LLC
--
0%
+78.28K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-788.50K
-100.00%
The Vanguard Group, Inc.
--
0%
-259.83K
-100.00%
New Enterprise Associates (NEA)
--
0%
--
--
View more
Related ETFs
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Name
Proportion
AltShares Merger Arbitrage ETF
1.12%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
View more
AltShares Merger Arbitrage ETF
Proportion1.12%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Inozyme Pharma Inc?
The top five shareholders of Inozyme Pharma Inc are:
Beryl Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Longitude Capital Management Co., LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Sofinnova Investments, Inc holds 0.00 shares, accounting for 0.00% of the total shares.
Glazer Capital, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 0.00 shares, accounting for 0.00% of the total shares.
Beryl Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Longitude Capital Management Co., LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Sofinnova Investments, Inc holds 0.00 shares, accounting for 0.00% of the total shares.
Glazer Capital, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Inozyme Pharma Inc?
The top three shareholder types of Inozyme Pharma Inc are:
Beryl Capital Management, LLC
Longitude Capital Management Co., LLC
Adage Capital Management, L.P.
Beryl Capital Management, LLC
Longitude Capital Management Co., LLC
Adage Capital Management, L.P.
How many institutions hold shares of Inozyme Pharma Inc (INZY)?
As of 2025Q2, 217 institutions hold shares of Inozyme Pharma Inc, with a combined market value of approximately 63.12M, accounting for 97.77% of the total shares. Compared to 2025Q1, institutional shareholding has increased by 12.25%.
What is the biggest source of revenue for Inozyme Pharma Inc?
In --, the -- business generated the highest revenue for Inozyme Pharma Inc, amounting to -- and accounting for --% of total revenue.
